These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 31179531)

  • 21. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
    Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
    Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.
    Scheffer IE; Hulihan J; Messenheimer J; Ali S; Keenan N; Griesser J; Gutterman DL; Sebree T; Sadleir LG
    JAMA Netw Open; 2021 Sep; 4(9):e2123930. PubMed ID: 34477852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
    Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H
    Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
    Privitera M; Bhathal H; Wong M; Cross JH; Wirrell E; Marsh ED; Mazurkiewicz-Beldzinska M; Villanueva V; Checketts D; Knappertz V; VanLandingham K
    Epilepsia; 2021 May; 62(5):1130-1140. PubMed ID: 33797076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
    Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
    Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy.
    Marchese F; Vari MS; Balagura G; Riva A; Salpietro V; Verrotti A; Citraro R; Lattanzi S; Minetti C; Russo E; Striano P
    Cannabis Cannabinoid Res; 2022 Apr; 7(2):199-206. PubMed ID: 33998856
    [No Abstract]   [Full Text] [Related]  

  • 30. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
    Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B
    Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
    CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
    Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
    BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients.
    Caraballo R; Valenzuela GR
    Seizure; 2021 Nov; 92():238-243. PubMed ID: 34624613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.
    Poisson K; Wong M; Lee C; Cilio MR
    Eur J Paediatr Neurol; 2020 Mar; 25():77-81. PubMed ID: 31926846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy.
    Cáceres Guido P; Riva N; Caraballo R; Reyes G; Huaman M; Gutierrez R; Agostini S; Fabiana Delaven S; Pérez Montilla CA; García Bournissen F; Schaiquevich P
    Epilepsia; 2021 Jan; 62(1):e7-e12. PubMed ID: 33280111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy.
    Riva A; D'Onofrio G; Pisati A; Roberti R; Amadori E; Bosch F; de Souza CFM; Thomas A; Russo E; Striano P; Bayat A
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):990-995. PubMed ID: 36862522
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.
    Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM
    Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.